This systematic review investigates the impact of GLP‐1‐based therapies on skeletal muscle mitochondrial function in individuals with obesity and T2DM or in related animal and cell models. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.